Asia Pacific Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Labora

Asia Pacific Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)     

The Asia Pacific (APAC) cervical cancer diagnostic testing market is expected to grow from US$ 936.22 million in 2021 to US$ 1,351.28 million by 2028. It is estimated to grow at a CAGR of 5.4% from 2021 to 2028. The cervical market players focus on launching new products to expand their geographic reach and enhance capacities to cater to a greater than existing customer base. In November 2021, Hologic, Inc. launched the Genius Digital Diagnostics System for cervical cancer screening. Next-generation screening systems combine deep earning-based artificial intelligence (AI) with the latest volumetric imaging technology to assess women's precancerous lesions and cervical cancer cells. Similarly, in 2019, BD's COR PX/GX system was launched, which has been available in centralized labs across the region to assist in high-volume processing and increase overall efficiency. Similarly, one popular government insurance program covers PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening. Such new products' programs, developments, and launches are likely to bring recent trends in the APAC cervical cancer diagnosis test market in the coming years, thereby supporting its growth.

In case of COVID-19, APAC, especially India, has been highly affected. APAC countries are witnessing significant challenges due to increasing COVID-19 cases. Given the current economic scenario, healthcare companies have poorly been impacted due to the outbreak. The outbreak has severely affected the tourism industry and imposed supply chain disruptions. Moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. All these factors will impact the cervical cancer diagnostic test market for a short period. The governments in the region are more focused on the treatment of COVID 19. Hospitals and surgical centers are open only for emergency services. China is explicitly facing issues that this epidemic has caused, leading to disruption of the supply chain, projected decreases in revenue and sales within all industries, and health concerns within production factories and other public spaces. Medical tourism is declined in response to the pandemic in countries, such as South Korea and Japan, reducing the revenue. Thus, it is expected to harm the cervical cancer diagnostic test market during the forecast period.

Based on type, the HPV testing segment is expected to be the fastest-growing segment over the forecast period. HPVs are a group of more than 150 related viruses. Some types of HPV can cause cancer, including cancers of the cervix, vagina, vulva, and other parts. HPV is of two types Cutaneous and Mucosal. The market player operating the related diagnostic markets are actively involved in market developments. HPV testing among the emerging segment in the market in the forecast period. Active product introduction in the untapped markets by the market is expected to support the market growth. Moreover, HPV testing is gaining preference over PAP. HPV testing offers a variety of options, such as at-home tests and point-of-care testing.

The overall size of the APAC cervical cancer diagnostic testing market has been derived using both primary and secondary sources. For the research, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the APAC cervical cancer diagnostic testing market. The process also serves the purpose of obtaining an overview and forecast for the market concerning all segments related to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data and gain more analytical insights into the topic. The participants who typically take part in such a process include industry experts, such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants, such as valuation experts, research analysts, and key opinion leaders, specializing in the APAC cervical cancer diagnostic testing market. Abbott; BD; Cooper Companies, Inc.; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are a few players in this regional market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC cervical cancer diagnostic testing market.    
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC cervical cancer diagnostic testing market, thereby allowing players across the value chain to develop effective long-term strategies 
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the cervical cancer diagnostic testing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution